|
Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series
|
Jan 2021
|
Annals of Hematology
|
aplastic anemia
|
|
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management"
|
Jan 2021
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)
|
|
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
|
Jan 2021
|
Therapeutic Advances in Hematology
|
myelodysplastic syndromes (MDS)
|
|
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
|
Jan 2021
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology
|
myelodysplastic syndromes (MDS)
|
|
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes
|
Jan 2021
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
|
How I Treat Paroxysmal nocturnal hemoglobinuria
|
Jan 2021
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria
|
Jan 2021
|
Leukemia
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
|
Jan 2021
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
|
Jan 2021
|
Cancer Management and Research
|
myelodysplastic syndromes (MDS)
|
|
Luspatercept in the treatment of lower-risk myelodysplastic syndromes
|
Jan 2021
|
Future Oncology (London, England)
|
myelodysplastic syndromes (MDS)
|
